We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Collegium’s Abuse-deterrent Xtampza Gets Unanimous FDA Panel Support
Collegium’s Abuse-deterrent Xtampza Gets Unanimous FDA Panel Support
A joint FDA advisory panel voted unanimously Friday to recommend Collegium Pharmaceutical’s Xtampza ER NDA, deciding that the possible risks related to food effects on the opioid’s efficacy were forgiving and not likely to pose serious safety challenges.